Last: | $4.805 |
---|---|
Change Percent: | 4.57% |
Open: | $4.58 |
Close: | $4.805 |
High: | $5 |
Low: | $4.55 |
Volume: | 2,265,701 |
Last Trade Date Time: | 03/19/2021 04:10:44 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.805 | $4.58 | $4.805 | $5 | $4.55 | 2,265,701 | 03-19-2021 |
$4.53 | $4.81 | $4.53 | $4.92 | $4.5 | 728,026 | 03-18-2021 |
$3.72 | $3.91 | $3.72 | $4.1 | $3.01 | 2,943,556 | 03-05-2021 |
$3.9 | $4.6 | $3.9 | $4.6131 | $3.77 | 1,369,389 | 03-04-2021 |
$4.33 | $4.66 | $4.33 | $4.78 | $4.24 | 1,126,697 | 03-03-2021 |
$4.55 | $4.97 | $4.55 | $5.13 | $4.47 | 2,720,099 | 03-02-2021 |
$4.88 | $5.13 | $4.88 | $5.24 | $4.87 | 1,267,579 | 03-01-2021 |
$4.92 | $5.24 | $4.92 | $5.59 | $4.92 | 948,246 | 02-26-2021 |
$5.34 | $5.6 | $5.34 | $5.8 | $5.23 | 791,594 | 02-25-2021 |
$5.86 | $5.8 | $5.86 | $6.21 | $5.7173 | 537,357 | 02-24-2021 |
$5.79 | $5.6 | $5.79 | $5.9238 | $5.23 | 1,422,454 | 02-23-2021 |
$6.19 | $6.39 | $6.19 | $6.5 | $5.96 | 1,302,089 | 02-22-2021 |
$6.34 | $5.55 | $6.34 | $6.5 | $5.55 | 1,124,516 | 02-19-2021 |
$6.19 | $6.1 | $6.19 | $6.2917 | $5.6106 | 915,270 | 02-18-2021 |
$6.37 | $6.49 | $6.37 | $6.49 | $6.2 | 923,566 | 02-17-2021 |
$6.5 | $6.07 | $6.5 | $6.53 | $5.85 | 1,846,570 | 02-16-2021 |
$5.92 | $5.69 | $5.92 | $5.97 | $5.51 | 984,674 | 02-15-2021 |
$5.92 | $5.69 | $5.92 | $5.97 | $5.51 | 984,455 | 02-12-2021 |
$5.75 | $6.01 | $5.75 | $6.05 | $5.4 | 1,365,180 | 02-11-2021 |
$5.85 | $6.45 | $5.85 | $6.57 | $5.35 | 2,573,168 | 02-10-2021 |
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that CEO J...
IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at t...
- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has...